Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: The ISIS randomized controlled trial

Margaret Rosenfeld, Felix Ratjen, Lyndia Brumback, Stephen Daniel, Ron Rowbotham, Sharon McNamara, Robin Johnson, Richard Kronmal, Stephanie Davis

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Context: Inhaled hypertonic saline is recommended as therapy for patients 6 years or older with cystic fibrosis (CF), but its efficacy has never been evaluated in patients younger than 6 years with CF. Objective: To determine if hypertonic saline reduces the rate of protocol-defined pulmonary exacerbations in patients younger than 6 years with CF. Design, Setting, and Participants: The Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS), a multicenter, randomized, double-blind, placebo-controlled trial conducted from April 2009 to October 2011 at 30 CF care centers in the United States and Canada. Participants were aged 4 to 60 months and had an established diagnosis of CF. A total of 344 patients were assessed for eligibility; 321 participants were randomized; 29 (9%) withdrew prematurely. Intervention: The active treatment group (n=158) received7%hypertonic saline and the control group (n=163) received 0.9% isotonic saline, nebulized twice daily for 48 weeks. Both groups received albuterol or levalbuterol prior to each study drug dose. Main Outcome Measures: Rate during the 48-week treatment period of protocol-defined pulmonary exacerbations treated with oral, inhaled, or intravenous antibiotics. Results: The mean pulmonary exacerbation rate (events per person-year) was 2.3 (95% CI, 2.0-2.5) in the active treatment group and 2.3 (95% CI, 2.1-2.6) in the control group; the adjusted rate ratio was 0.98 (95% CI, 0.84-1.15). Among participants with pulmonary exacerbations, the mean number of total antibiotic treatment days for a pulmonary exacerbation was 60 (95% CI, 49-70) in the active treatment group and 52 (95% CI, 43-61) in the control group. There was no significant difference in secondary end points including height, weight, respiratory rate, oxygen saturation, cough, or respiratory symptom scores. Infant pulmonary function testing performed as an exploratory outcome in a subgroup (n=73, with acceptable measurements at 2 visits in 45 participants) did not demonstrate significant differences between groups except for the mean change in forced expiratory volume in 0.5 seconds, which was 38 mL (95% CI, 1-76) greater in the active treatment group. Adherence determined by returned study drug ampoules was at least 75% in each group. Adverse event profiles were also similar, with the most common adverse event of moderate or severe severity in each group being cough (39% of active treatment group, 38% of control group). Conclusion: Among infants and children younger than 6 years with cystic fibrosis, the use of inhaled hypertonic saline compared with isotonic saline did not reduce the rate of pulmonary exacerbations over the course of 48 weeks of treatment. Trial Registration: clinicaltrials.gov Identifier: NCT00709280.

Original languageEnglish
Pages (from-to)2269-2277
Number of pages9
JournalJournal of the American Medical Association
Volume307
Issue number21
DOIs
StatePublished - May 30 2012

Fingerprint

Cystic Fibrosis
Randomized Controlled Trials
Lung
Control Groups
Therapeutics
Cough
Levalbuterol
Anti-Bacterial Agents
Albuterol
Forced Expiratory Volume
Respiratory Rate
Clinical Protocols
Pharmaceutical Preparations
Canada
Placebos
Outcome Assessment (Health Care)
Oxygen
Weights and Measures

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis : The ISIS randomized controlled trial. / Rosenfeld, Margaret; Ratjen, Felix; Brumback, Lyndia; Daniel, Stephen; Rowbotham, Ron; McNamara, Sharon; Johnson, Robin; Kronmal, Richard; Davis, Stephanie.

In: Journal of the American Medical Association, Vol. 307, No. 21, 30.05.2012, p. 2269-2277.

Research output: Contribution to journalArticle

Rosenfeld, Margaret ; Ratjen, Felix ; Brumback, Lyndia ; Daniel, Stephen ; Rowbotham, Ron ; McNamara, Sharon ; Johnson, Robin ; Kronmal, Richard ; Davis, Stephanie. / Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis : The ISIS randomized controlled trial. In: Journal of the American Medical Association. 2012 ; Vol. 307, No. 21. pp. 2269-2277.
@article{3696c79142394649bc1596f92ada9847,
title = "Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: The ISIS randomized controlled trial",
abstract = "Context: Inhaled hypertonic saline is recommended as therapy for patients 6 years or older with cystic fibrosis (CF), but its efficacy has never been evaluated in patients younger than 6 years with CF. Objective: To determine if hypertonic saline reduces the rate of protocol-defined pulmonary exacerbations in patients younger than 6 years with CF. Design, Setting, and Participants: The Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS), a multicenter, randomized, double-blind, placebo-controlled trial conducted from April 2009 to October 2011 at 30 CF care centers in the United States and Canada. Participants were aged 4 to 60 months and had an established diagnosis of CF. A total of 344 patients were assessed for eligibility; 321 participants were randomized; 29 (9{\%}) withdrew prematurely. Intervention: The active treatment group (n=158) received7{\%}hypertonic saline and the control group (n=163) received 0.9{\%} isotonic saline, nebulized twice daily for 48 weeks. Both groups received albuterol or levalbuterol prior to each study drug dose. Main Outcome Measures: Rate during the 48-week treatment period of protocol-defined pulmonary exacerbations treated with oral, inhaled, or intravenous antibiotics. Results: The mean pulmonary exacerbation rate (events per person-year) was 2.3 (95{\%} CI, 2.0-2.5) in the active treatment group and 2.3 (95{\%} CI, 2.1-2.6) in the control group; the adjusted rate ratio was 0.98 (95{\%} CI, 0.84-1.15). Among participants with pulmonary exacerbations, the mean number of total antibiotic treatment days for a pulmonary exacerbation was 60 (95{\%} CI, 49-70) in the active treatment group and 52 (95{\%} CI, 43-61) in the control group. There was no significant difference in secondary end points including height, weight, respiratory rate, oxygen saturation, cough, or respiratory symptom scores. Infant pulmonary function testing performed as an exploratory outcome in a subgroup (n=73, with acceptable measurements at 2 visits in 45 participants) did not demonstrate significant differences between groups except for the mean change in forced expiratory volume in 0.5 seconds, which was 38 mL (95{\%} CI, 1-76) greater in the active treatment group. Adherence determined by returned study drug ampoules was at least 75{\%} in each group. Adverse event profiles were also similar, with the most common adverse event of moderate or severe severity in each group being cough (39{\%} of active treatment group, 38{\%} of control group). Conclusion: Among infants and children younger than 6 years with cystic fibrosis, the use of inhaled hypertonic saline compared with isotonic saline did not reduce the rate of pulmonary exacerbations over the course of 48 weeks of treatment. Trial Registration: clinicaltrials.gov Identifier: NCT00709280.",
author = "Margaret Rosenfeld and Felix Ratjen and Lyndia Brumback and Stephen Daniel and Ron Rowbotham and Sharon McNamara and Robin Johnson and Richard Kronmal and Stephanie Davis",
year = "2012",
month = "5",
day = "30",
doi = "10.1001/jama.2012.5214",
language = "English",
volume = "307",
pages = "2269--2277",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "21",

}

TY - JOUR

T1 - Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis

T2 - The ISIS randomized controlled trial

AU - Rosenfeld, Margaret

AU - Ratjen, Felix

AU - Brumback, Lyndia

AU - Daniel, Stephen

AU - Rowbotham, Ron

AU - McNamara, Sharon

AU - Johnson, Robin

AU - Kronmal, Richard

AU - Davis, Stephanie

PY - 2012/5/30

Y1 - 2012/5/30

N2 - Context: Inhaled hypertonic saline is recommended as therapy for patients 6 years or older with cystic fibrosis (CF), but its efficacy has never been evaluated in patients younger than 6 years with CF. Objective: To determine if hypertonic saline reduces the rate of protocol-defined pulmonary exacerbations in patients younger than 6 years with CF. Design, Setting, and Participants: The Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS), a multicenter, randomized, double-blind, placebo-controlled trial conducted from April 2009 to October 2011 at 30 CF care centers in the United States and Canada. Participants were aged 4 to 60 months and had an established diagnosis of CF. A total of 344 patients were assessed for eligibility; 321 participants were randomized; 29 (9%) withdrew prematurely. Intervention: The active treatment group (n=158) received7%hypertonic saline and the control group (n=163) received 0.9% isotonic saline, nebulized twice daily for 48 weeks. Both groups received albuterol or levalbuterol prior to each study drug dose. Main Outcome Measures: Rate during the 48-week treatment period of protocol-defined pulmonary exacerbations treated with oral, inhaled, or intravenous antibiotics. Results: The mean pulmonary exacerbation rate (events per person-year) was 2.3 (95% CI, 2.0-2.5) in the active treatment group and 2.3 (95% CI, 2.1-2.6) in the control group; the adjusted rate ratio was 0.98 (95% CI, 0.84-1.15). Among participants with pulmonary exacerbations, the mean number of total antibiotic treatment days for a pulmonary exacerbation was 60 (95% CI, 49-70) in the active treatment group and 52 (95% CI, 43-61) in the control group. There was no significant difference in secondary end points including height, weight, respiratory rate, oxygen saturation, cough, or respiratory symptom scores. Infant pulmonary function testing performed as an exploratory outcome in a subgroup (n=73, with acceptable measurements at 2 visits in 45 participants) did not demonstrate significant differences between groups except for the mean change in forced expiratory volume in 0.5 seconds, which was 38 mL (95% CI, 1-76) greater in the active treatment group. Adherence determined by returned study drug ampoules was at least 75% in each group. Adverse event profiles were also similar, with the most common adverse event of moderate or severe severity in each group being cough (39% of active treatment group, 38% of control group). Conclusion: Among infants and children younger than 6 years with cystic fibrosis, the use of inhaled hypertonic saline compared with isotonic saline did not reduce the rate of pulmonary exacerbations over the course of 48 weeks of treatment. Trial Registration: clinicaltrials.gov Identifier: NCT00709280.

AB - Context: Inhaled hypertonic saline is recommended as therapy for patients 6 years or older with cystic fibrosis (CF), but its efficacy has never been evaluated in patients younger than 6 years with CF. Objective: To determine if hypertonic saline reduces the rate of protocol-defined pulmonary exacerbations in patients younger than 6 years with CF. Design, Setting, and Participants: The Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS), a multicenter, randomized, double-blind, placebo-controlled trial conducted from April 2009 to October 2011 at 30 CF care centers in the United States and Canada. Participants were aged 4 to 60 months and had an established diagnosis of CF. A total of 344 patients were assessed for eligibility; 321 participants were randomized; 29 (9%) withdrew prematurely. Intervention: The active treatment group (n=158) received7%hypertonic saline and the control group (n=163) received 0.9% isotonic saline, nebulized twice daily for 48 weeks. Both groups received albuterol or levalbuterol prior to each study drug dose. Main Outcome Measures: Rate during the 48-week treatment period of protocol-defined pulmonary exacerbations treated with oral, inhaled, or intravenous antibiotics. Results: The mean pulmonary exacerbation rate (events per person-year) was 2.3 (95% CI, 2.0-2.5) in the active treatment group and 2.3 (95% CI, 2.1-2.6) in the control group; the adjusted rate ratio was 0.98 (95% CI, 0.84-1.15). Among participants with pulmonary exacerbations, the mean number of total antibiotic treatment days for a pulmonary exacerbation was 60 (95% CI, 49-70) in the active treatment group and 52 (95% CI, 43-61) in the control group. There was no significant difference in secondary end points including height, weight, respiratory rate, oxygen saturation, cough, or respiratory symptom scores. Infant pulmonary function testing performed as an exploratory outcome in a subgroup (n=73, with acceptable measurements at 2 visits in 45 participants) did not demonstrate significant differences between groups except for the mean change in forced expiratory volume in 0.5 seconds, which was 38 mL (95% CI, 1-76) greater in the active treatment group. Adherence determined by returned study drug ampoules was at least 75% in each group. Adverse event profiles were also similar, with the most common adverse event of moderate or severe severity in each group being cough (39% of active treatment group, 38% of control group). Conclusion: Among infants and children younger than 6 years with cystic fibrosis, the use of inhaled hypertonic saline compared with isotonic saline did not reduce the rate of pulmonary exacerbations over the course of 48 weeks of treatment. Trial Registration: clinicaltrials.gov Identifier: NCT00709280.

UR - http://www.scopus.com/inward/record.url?scp=84861892411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861892411&partnerID=8YFLogxK

U2 - 10.1001/jama.2012.5214

DO - 10.1001/jama.2012.5214

M3 - Article

C2 - 22610452

AN - SCOPUS:84861892411

VL - 307

SP - 2269

EP - 2277

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 21

ER -